2022·6th Future Healthcare 100 Summit Kicks Off in Suzhou on April 22, Showcasing China's Innovation Story

/

Oracle bone script is the earliest known mature writing system currently visible in China. Its emergence provided Chinese civilization with a tool for recording and transmitting knowledge. From individuals to entire communities, all emotions, knowledge, thoughts, and experiences have been passed down through generations via written language, enabling the shaping and dissemination of the story of Chinese civilization.

"This is an ancient Chinese tale, where the wisdom and creativity of our ancestors have left a mysterious and romantic foundation for the development of world civilization."Over five millennia, the stars have shifted and time has turned; from East to West, history moves in cycles. Today, the world’s gaze once again focuses on China. This time, China is annotating its narrative with innovation, charting a blueprint for the future development of technology.

In June 2021, the World Health Organization (WHO) added the inactivated COVID-19 vaccines developed by Sinopharm’s Beijing Institute of Biological Products and Sinovac’s Beijing Kexing Zhongwei to its Emergency Use Listing. To date, Sinopharm China National Biotec Group’s (CNBG) COVID-19 vaccine has been approved for registration, marketing, or emergency use in 70 countries, regions, and international organizations worldwide. More than 100 countries and international organizations have expressed procurement demands, with over 200 million doses supplied domestically and internationally, and vaccination coverage extending to populations in 196 countries.

In December 2021, the combination therapy of neutralizing antibodies against SARS-CoV-2, independently developed by Brii Biosciences, received review and approval from the National Medical Products Administration (NMPA) for the treatment of patients with novel coronavirus infection (COVID-19). From research to approval, this innovative COVID-19 drug took just over one year.

Not only in the field of COVID-19 research, but in recent years, multiple niche sectors of the medical device industry have achieved zero-to-one breakthroughs in domestic production, with some even pioneering innovative technologies that lead the world.

Taking cardiovascular stents as an example,Prior to 2004, the domestic coronary stent market was monopolized by multinational giants such as Johnson & Johnson, Medtronic, and Boston Scientific. This landscape was disrupted in 2004 and 2005 when MicroPort and Lepu Medical sequentially launched domestically produced drug-eluting coronary stents. Currently, domestic brands Lepu, MicroPort, and Jiwei collectively hold over 70% of the cardiac stent market share, indicating that domestic brands have begun to dominate the market.

In the heart valve sector,Currently, two domestic transcatheter mitral valve replacement (TMVR) products are leading the industry in R&D progress: MitraFix by Venus MedTech and Mithos by MicroPort CardioFlow. Both have entered the product registration application phase. Globally, among TMVR products, only Abbott’s Tendyne received CE Mark approval in Europe in February 2020, while the U.S. FDA has not yet granted marketing authorization for any such product. The development timelines of Venus MedTech’s MitraFix and MicroPort CardioFlow’s Mithos are comparable to that of Edwards Lifesciences’ EVOQUE system, placing them at the forefront globally. Market launch within the next one to two years is anticipated.

Neurointerventional FieldIt also shines brightly in the international market.For example, Vascular Interventional Medical’s neurointerventional products have been exported to more than 20 countries and regions, including the United States, Germany, the United Kingdom, and Japan; Jiushi Shenkang has collaborated with Israeli medical device manufacturer Perflow on product registration, research and development, market access, and distribution, helping each other accelerate their internationalization processes.

......

An increasing number of Chinese enterprises are emerging on the international stage, seeking cooperation and pursuing mutual development through active global engagement. China cannot thrive without the world, and the world needs China.Undoubtedly, this is the best of times, and an age of wisdom.As a cornerstone industry of the national economy, healthcare is relevant to every individual. We are confident that future world-class healthcare enterprises will emerge from China, and we look forward to seeing world-class innovations originating in China spread with prairie-fire momentum.

As an observer and recorder of the healthcare industry, VB100 accompanies innovative enterprises and a new generation of scientists in their growth, serving as their trusted partner. We provide a ladder for innovators, enabling them to advance with stability and confidence. This year, we have continued to pursue endeavors worth sustaining. The “Future Healthcare Top 100 Conference,” a premier healthcare event created by VB100, has been successfully held for five consecutive editions, attracting nearly 20,000 industry professionals. It has now become the largest and most information-rich conference in China’s healthcare innovation sector, fostering deep integration between industry and capital.

After a 365-day wait, the 6th Future Healthcare 100 Conference embarks on a new journey, focusing on the theme of “China Stories.” It is scheduled to be held from April 22 to April 24, 2022, at the Shishan International Convention Center in Suzhou, Jiangsu Province.

Why Suzhou?

“As there is paradise in heaven, there are Suzhou and Hangzhou on earth.” The beauty of Suzhou has been celebrated for millennia, yet the charm of this Jiangnan city extends far beyond its scenic allure. As the largest economy in Jiangsu Province, Suzhou’s gross domestic product (GDP) surpassed RMB 2 trillion in 2020. On the list of “Top 10 Chinese Cities by GDP in 2020,” Suzhou ranked sixth, standing as the only prefecture-level city among the top ten.

Among these, the biopharmaceutical industry is a crucial link in Suzhou’s economic chain. The nationally renowned BioBAY (hereinafter referred to as “BioBAY”) is located in Suzhou. To date, BioBAY has gathered more than 1,700 related enterprises, with an output value reaching the hundred-billion-yuan level, accounting for over 50% of the city’s total biopharmaceutical industry. In addition to BioBAY, the Jiangsu Medical Device Technology Industrial Park (hereinafter referred to as “Medpark”), established through collaboration between the Suzhou New District Government and the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, brings together leading domestic medical device companies and innovative enterprises, striving to build the internationally influential “Medpark” brand. Suzhou is emerging as a rising star city that converges high-end medical and health resources.

As a platform and vehicle for medical industry resources, the Future Healthcare Top 100 Conference has chosen to settle in Suzhou, aiming to explore greater possibilities at the crossroads of medical industry innovation during the vibrant April season, when distinguished guests gather amidst pleasant spring scenery.

Conference Theme: “China Story”

Conference Dates: April 22–24, 2022

Venue: Suzhou Shishan International Convention Center

I. Led by Nobel Laureates and Academicians, Featuring a Lineup of 300 Top-Tier Guests

Led by Nobel Laureates, Academicians, and IEEE Fellows300 individualsClinical experts, leading researchers from universities, investors, and industry leaders, conduct3-day durationSharing of cutting-edge medical technologies, industry trends, and business innovations;

II. Tell China’s Stories Well and Look to Overseas Markets

Focusing on the innovation strategies and overseas market expansion of Chinese innovative enterprises, connecting with high-quality overseas projects

III. 100+ Financial Institutions, Deeply Integrated into the Capital Industry Chain

Compilation100+ContainsGP/LP/CVC/VC/PE/FAetc., focusing on internal relationships within the capital market and the reshaping of the capital industrial chain

IV. Innovation-Driven, Linking Primary and Secondary Markets

Top 100 ListSystem Upgrade: Addition of Secondary Marketinteractive communication;Listed Companies and Unicorn EnterprisesStrategic Announcements; Trend Sharing and Industry Insights from Primary and Secondary Market Fund Managers;

V. Buzz and Depth: 20+ Forum Themes

Major AnnouncementN copiesIndustry Research Series Report;20+Thematic Forum: Exploring Development Trends and Innovative Practices in Niche Segments of Biomedicine, Innovative Medical Devices, Healthcare Services, and Digital Health

VI. Connect with Partners to Harness Ecosystem Momentum

Professional and PreciseTop 100 Exhibitions+ Open up the conference ecosystem, partner with 10+ investment institutions and industry giants, build an ecosystem forum, and connect100+ Media Outlets, nationwide multi-platform coordinationTens of Millions in Influence；

(The forum structure is subject to the actual conference agenda.)

(The forum structure is subject to the actual conference agenda)

(The forum structure is subject to the actual conference agenda.)

Media/Institutional Support

/

Conference Dates: April 22-24, 2022

Conference Venue: Shishan International Conference Center, Suzhou, China

Limited-Time Offer: Early Bird Tickets

Purchase Channels:Search for the “VB100” mini program on WeChat to make a purchase.

Two types of general admission passes are available for public sale at this conference:

899 Yuan [VB100 All-Access Pass, Meals Not Included]

1,299 Yuan [Meal-Inclusive VB100 All-Access Pass]

Early bird tickets and general admission tickets are now on sale.¥700 off the original price, now as low as ¥169Onset:

Your trust will grant you the following benefits:

1. All-Access Pass for Forum, Exhibition, and Interactive Activities (Separate registration required for certain invitation-only sessions)

2. On-Site Resource Coordination Group Chat

3. Guest-authorized limited materials, including PPTs, conference proceedings, and public reports

4. Lunch vouchers during the conference (only for tickets including meals)

Special Note:

1. Limited-Time Early Bird Ticket Offer PeriodFrom today until February 28, 2022;

2. Ticket prices will be adjusted as information regarding the conference theme, speakers, topics, and exhibitors is unveiled,Increase by 100 yuan each time until the original price is restored;

3、After the early bird ticket discount ends,Ticket prices will rise to 269 yuanStart

Scan the QR code to register for the 2022·6th Future Healthcare Top 100 Conference